Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nintedanib + nivolumab
- Development stage
- Phase 2
- Lead developer
- Boehringer Ingelheim
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Nintedanib + nivolumab is an investigational combination therapy for cancer, particularly advanced non-small cell lung cancer (NSCLC). Nintedanib is an oral small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR 1–3), fibroblast growth factor receptors (FGFR 1–3), and platelet-derived growth factor receptors (PDGFR α/β), thereby inhibiting angiogenesis, tumor proliferation, and the activity of immunosuppressive cancer-associated fibroblasts in the tumor microenvironment. Nivolumab is a monoclonal antibody immune checkpoint inhibitor targeting programmed death 1 receptor (PD-1) on T cells, enhancing anti-tumor immune responses. The rationale for combining these agents is to synergistically improve immunotherapy outcomes by modulating both the tumor vasculature/microenvironment and immune response. This combination has been evaluated in phase I/II clinical trials for advanced NSCLC[1][2][10].
- Brand names
- Vargatef
- Other names
- nintedanib + nivolumab
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on nintedanib + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nintedanib + nivolumab.